Background: Breast cancer is associated with a multitude of risk factors, such as genetic predisposition and mutations, family history, personal medical history, or previous radiotherapy. A prophylactic mastectomy (PM) may be considered a suitable risk-reducing procedure in some cases. However, there are significant discrepancies between national society recommendations and insurance company requirements for PM.
Materials and methods: The authors conducted a cross-sectional analysis of insurance policies for a PM. One-hundred companies were selected based on the greatest state enrolment and market share. Their policies were identified through a Web-based search and telephone interviews, and their medical necessity criteria were extracted.
Results: Preauthorized coverage of PMs was provided by 39% of insurance policies (n = 39) and 5 indications were identified. There was consensus amongst these policies to cover a PM for BRCA1/2 mutations (n = 39, 100%), but was more variable for other genetic mutations (15%-90%). Coverage of PM for the remaining indications varied among insurers: previous radiotherapy (92%), pathological changes in the breast (3%-92%), personal history of cancer (64%) and family history risk factors (39%-51%).
Conclusion: There is a marked level of variability in both the indications and medical necessity criteria for PM insurance policies. The decision to undergo a PM must be carefully considered with a patient's care team and should not be affected by insurance coverage status.
Keywords: Breast; Breast neoplasms; Hereditary cancer syndromes; Insurance XCoverage; Mastectomy; Prophylactic mastectomy; Prophylactic surgical procedures; Risk reduction.
Copyright © 2022 Elsevier Inc. All rights reserved.
Disclosure The authors have stated that they have no conflicts of interest.
Ha M, Ngaage LM, Klein M, Yang A, Colohan SM, Nurudeen SM, Terhune JH, Slezak S, Rasko YM. Ha M, et al. Breast J. 2021 Oct;27(10):746-752. doi: 10.1111/tbj.14280. Epub 2021 Sep 15. Breast J. 2021. PMID: 34528334
Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ. Kuerer HM, et al. Ann Surg Oncol. 2000 Jun;7(5):325-32. doi: 10.1007/s10434-000-0325-1. Ann Surg Oncol. 2000. PMID: 10864338
Klein M, Ha M, Yang A, Ngaage LM, Slezak S, Rasko Y. Klein M, et al. Ann Plast Surg. 2021 Sep 1;87(3):232-237. doi: 10.1097/SAP.0000000000002871. Ann Plast Surg. 2021. PMID: 34397512
Finkelstein ER, Ha M, Hanwright P, Ngaage LM, Yoon JS, Liang F, Nam AJ, Rasko YM. Finkelstein ER, et al. J Vasc Surg Venous Lymphat Disord. 2022 Jul;10(4):929-936. doi: 10.1016/j.jvsv.2022.03.008. Epub 2022 Mar 29. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35364303 Review.
Lostumbo L, Carbine N, Wallace J, Ezzo J. Lostumbo L, et al. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3. PMID: 15495033 Updated. Review.